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Abstract
HIV epidemiology informs prevention trial design and program planning. Nine clinical re-
search centers (CRC) in sub-Saharan Africa conducted HIV observational epidemiology
studies in populations at risk for HIV infection as part of an HIV prevention and vaccine trial
network. Annual HIV incidence ranged from below 2% to above 10% and varied by CRC
and risk group, with rates above 5% observed in Zambian men in an HIV-discordant rela-
tionship, Ugandan men from Lake Victoria fishing communities, men who have sex with
men, and several cohorts of women. HIV incidence tended to fall after the first three months
in the study and over calendar time. Among suspected transmission pairs, 28% of HIV in-
fections were not from the reported partner. Volunteers with high incidence were success-
fully identified and enrolled into large scale cohort studies. Over a quarter of new cases in
couples acquired infection from persons other than the suspected transmitting partner.
Introduction
The African continent is disproportionately affected by the HIV pandemic. Despite represent-
ing only 12% of the world’s population, sub-Saharan Africa bears nearly 70% of the world’s
cases of HIV [1] and the epidemic there is complex [2]. The greatest diversity of HIV subtypes
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is found across Africa, primarily subtypes A, C, D and their recombinants, and this varies by
region [3]. Modes of transmission and affected populations are equally diverse, and can change
over time. While the epidemic is primarily heterosexual [4], other key populations including
men who have sex with men [5] may also contribute to HIV transmission regionally. Policy
makers and clinical trialists depend on epidemiology data to guide effective prevention plan-
ning, service delivery [6, 7] and design and conduct of prevention trials [2, 8, 9].
HIV surveillance systems have often relied on cross sectional surveys of HIV infection [10].
While prevalence data may provide some indication of risk groups and can provide guidance
for service delivery, they fail to identify recently infected persons. Though there is some prog-
ress being made on assays to estimate incidence from prevalent samples [11], these assays have
yet to be proven valid, particularly in the African context [12, 13]. Furthermore, the increasing
availability of antiretroviral therapy throughout Africa is allowing persons with HIV to live
longer, making prevalence data even less relevant [14]. Research towards understanding and
preventing HIV transmission should ideally focus on incident cases of HIV. Large-scale HIV
incidence cohorts remain the gold standard for collecting these data.
Beginning in 1999 the International AIDS Vaccine Initiative (IAVI) undertook the funding
and development of in-country laboratory and clinical capacity at nine research centers in
Kenya, Uganda, Rwanda, Zambia and South Africa to support HIV vaccine trials. This work
included observational epidemiology studies designed to recruit key populations suitable for
trials, provide critical experience to the research teams, and inform the design of future HIV
prevention trials. In 2004 this network began multiple, large-scale studies of HIV prevalence,
incidence and early infection. Here we present the findings of these observational epidemiology
studies.
Methods
Clinical Research Network
This work was conducted at nine sites in South Africa, Zambia, Kenya, Uganda and Rwanda
(Fig. 1). All clinical research centers (CRC) are affiliated with existing institutions, locally
staffed and most are led by local clinician-scientists who are recognized experts on HIV. To en-
sure that studies are conducted according to the International Conference on Harmonization
Good Clinical Practices (ICH-GCP), GCP training is provided. HIV testing and counseling
training and support are provided to counseling staff through a continuous improvement pro-
cess. Specialized training addresses the needs of key populations such as men who have sex
with men [15] or married/cohabiting couples [16, 17]. Study clinics are equipped to provide
some care to volunteers (e.g., diagnosis and treatment of sexually transmitted diseases) and
local health care resources available for referral have been assessed and strengthened where
possible [18].
Laboratory facilities
All laboratories are equipped to perform tests for HIV antibody (rapid test for HIV, HIV
ELISA, and p24 ELISA), syphilis and pregnancy. To assure assay comparability across CRC,
quality assurance and control (QA/QC) is performed by Clinical Laboratory Services in Johan-
nesburg, South Africa. Laboratory personnel are trained in GCLP, and 8 of the nine research
centers in the network have now received GCLP accreditation through Qualogy (www.
qualogy.co.uk). The Rustenburg CRC did not adopt PBMC processing facilities, instead send-
ing sample to Johannesburg for processing, and therefore never qualified for GCLP accredita-
tion. Three labs were accredited in 2007 (Nairobi, Kilifi, Entebbe), one in 2008 (Kigali), one in
2009 (Lusaka), one in 2010 (Ndola) and one in 2011 (Masaka).
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HIV prevalence studies
Three CRCs (Nairobi, Masaka and Kilifi) enrolled 1,000–2,000 study volunteers, 18 years or
older, for a single visit to characterize local HIV prevalence and risk factors. HIV VCT em-
ployed two rapid tests (typically Determine and Unigold; with tiebreakers Murex in Masaka,
Vironostika in Nairobi, and Instascreen in Kilifi). A brief, site-specific, demographic and risk
assessment questionnaire was administered. In Nairobi, volunteers included sex workers and
their clients. In Masaka, the goal was to obtain a population-based estimate of prevalence and
therefore recruitment included all residents of three rural communities, recruited and provided
with HIV counseling and results at their homes. Home based counseling included pre-test
counseling and sample draw in the home, with delivery of results within 1–4 weeks. Subsequent
testing and counseling (in the incidence studies, below) was done in a local research clinic. In
Kilifi, study volunteers were recruited from three populations: 1) randomly selected residents
of the Kilifi Demographic Surveillance System (DSS), 2) walk-in VCT clients at the study site,
and 3) the referred sexual partners of DSS and walk-in volunteers.
HIV incidence studies
Methods for each cohort have been published separately (Table 1). Briefly, each CRC per-
formed community mapping, community-sensitization exercises, and/or prevalence studies,
and based on the results and their own area(s) of expertise, each team selected risk screening
criteria to enroll key populations. Teams reviewed enrollment criteria and HIV incidence in
real time to confirm enrollment of true key populations. The cohorts included: 1) HIV negative
partners of co-habiting, sexually active couples with an HIV infected, antiretroviral therapy
(ART)-naïve partner (Zambia; Rwanda; Entebbe, Uganda) or irrespective of ART status
(Masaka, Uganda); 2) sexually active sex workers and their clients (Kenya); 3) members of fish-
ing communities aged 13–49 years and reporting at least one of the following in the past 3
months: more than one partner, a new partner, a sexually transmitted infection (STI), absence
from home for more than 2 nights, regular sex partner who is HIV infected (Uganda; in Janu-
ary 2012, criteria were modified to ages 18–49 years, ART-naïve, report of alcohol/recreational
drug use, report of unprotected sex; more than one partner was dropped); 4) Men who have
sex with men (MSM; Kenya and Rustenburg); 4) younger participants recruited in Cape Town
Figure 1. Map of the collaborating research centers of the IAVI Africa HIV Prevention Partnership.
MRC/UVRI: Medical Research Council/Uganda Virus Research Institute, IAVI: International AIDS Vaccine
Initiative
doi:10.1371/journal.pone.0116100.g001
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(16 years) and in the first fishing community study (Uganda,13 years); and 5) geography
as a screening criterion, as in the recruitment of adult members of several study villages
(Masaka) and women living in peri-urban, economically disadvantaged regions with high HIV
prevalence (Rustenburg).
Volunteers were followed quarterly or monthly. Cohort sizes were selected to provide a ro-
bust estimate of HIV incidence in light of the challenges of recruiting marginalized popula-
tions, and ranged from 250–1,000 volunteers. At every visit, volunteers were given HIV
counseling and testing by both rapid test and p24 ELISA to detect HIV infection prior to anti-
body seroconversion (see references in Table 2). Rapid tests were typically performed by veni-
puncture and done in parallel. Condoms were provided, as was lubricant for the cohorts where
anal sex was prevalent. Sexual behavior questionnaires were administered quarterly in Kenya,
South Africa, Rwanda and Zambia; and every six months in Masaka. Cohorts with HIV inci-
dence persistently<2% are not presented here (e.g., [19, 20]). Volunteers with incident HIV
infection were invited to enroll in the early HIV infection study, 2006–2011, and had their
CD4 T cell counts and viral load done at regular intervals. These data were used to inform re-
ferrals for antiretroviral therapy provided per the national guidelines. CRCs maintained strong
relationships with local health care facilities to assure volunteers would be kept aware of and re-
ferred to as needed additional care and treatment as it became available (e.g., medical male cir-
cumcision) [21].
Early HIV infection study
The Early HIV Infection Study has been described previously [22, 23]. Briefly, volunteers iden-
tified with incident HIV infection were invited to enroll as early as possible (typically within
2 months of their estimated date of infection (EDI)) and follow-up is ongoing. Viral subtype
was determined by sequencing the pol region of HIV from an early sample [22]. Suspected
transmitting partners were invited to enroll, and molecular epidemiologic linkages were deter-
mined by sequence comparison of pol, gag, gp120, gp41, and/or long terminal repeat regions
[24].
Data collection and management
Data from the HIV prevalence studies were managed by CRC staff. HIV incidence and early in-
fection study data were managed by the Perinatal HIV Research Unit (PHRU) in Johannes-
burg, South Africa, except the incidence studies in Rwanda, Zambia, and some in Uganda,
which were managed by the CRC staff. Data were transcribed onto a DataFax (Clinical DataFax
Systems, Inc., Ontario, Canada) form and digitally faxed to a central server; manual and auto-
matic queries were received then resolved by the CRC data management team. An epidemiolo-
gist reviewed the data prior to analysis.
Data analysis
Inferential statistics include chi square or Wilcoxon rank-sum as appropriate. Predictors of
prevalent HIV were evaluated separately for different key populations. Covariates were selected
to remain in the multivariable model based on a p-value<0.05. Modeling results are shown as
p-values, prevalence ratios, and 95% confidence intervals. Comparisons of HIV incidence
across CRC or by gender were done by Cox Proportional Hazards modeling; analyses compar-
ing HIV incidence across time was done using the Stata incidence rate ratio calculator. Only
those cohorts with recruitment spread over> 3 years and with adequate follow-up (>400 PY)
were analyzed by year. Estimates that vary from published results are due to additional follow-
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Table 2. Enrollment and HIV incidence among at-risk volunteers enrolled for HIV prevention preparatory studies stratiﬁed by CRC and, where
appropriate, sex.
CRC and study
population
Enrollment
years
Year of last
study visit
Total
enrolled
Total
PY
HIV cases
detected
HIV
incidence
95% CI p value** ref.***
HIV discordant couples
Kigali, Rwanda Stephenson, 2008;
Wall, 2012
DC male negative 2002–11* 2011 972 1844 64 3.5 (2.7, 4.4) 0.16
DC female negative 2002–11* 2011 884 1705 45 2.6 (1.9, 3.5)
Lusaka, Zambia Kempf, 2008;
Stephenson, 2008
DC male negative 1995–11* 2011 1656 3367 226 6.7 (5.9, 7.7) 0.003
DC female negative 1995–11* 2011 1393 2848 252 8.9 (7.8, 10.0)
Ndola, Zambia Lambdin, 2011
DC male negative 2004–11 2011 416 575 35 6.1 (4.2, 8.5) 0.01
DC female negative 2004–11 2011 335 399 43 10.8 (7.8, 14.5)
Masaka, Uganda Ruzagira, 2011 (a)
DC male negative 2006–11 2011 581 1143 44 3.8 (2.9, 5.2) 0.44
DC female negative 2006–11 2011 313 514 24 4.7 (3.1, 7.0)
Masaka, Uganda Ruzagira, 2011 (a)
DC on ART1 2006–09 2009 152 271 3 1.1 (0, 2.4) —
Entebbe, Uganda NA
DC male negative 2006–09 2010 276 345 5 1.4 (0.6, 3.5) 0.27
DC female negative 2006–09 2010 322 416 11 2.6 (1.5, 4.8)
Men who have sex with
men
Kiliﬁ, Kenya 2005–2012▪ 2013▪ 726 996 73 7.3 (5.8–9.2) — Price, 2012; Sanders,
2013
Nairobi, Kenya 2006–09 2010 303 338 19 5.6 (3.6, 8.8) — Price, 2012
Rustenburg, South
Africa
2009–10 2011 29 21 2 9.5 (2.4, 38.0) — NA
At-risk women
Cape Town, South
Africa
Price, 2012
Younger women▪▪ 2006–7 2008 337 284 8 2.8 (1.4, 5.6) —
Rustenburg, South
Africa
Women, clinic and
community based
2008–9 2009 223 67 2 3.0 (0.4, 10.8) — Feldblum, 2012
Peripheral community
residents
2010–11 2012 323 213 19 8.9 (5.7, 14.0) — NA
Kiliﬁ, Kenya Price, 2012
Female sex workers 2005–2010 2012 315 552 13 2.4 (1.4, 4.1) —
Fishing Community
members
Masaka, Uganda NA
Male 2012–13 2013▪ 327 244 13 5.3 (3.1, 9.2) 0.10
Female 2012–13 2013▪ 217 139 14 10.1 (6.0, 17.0)
Masaka and Entebbe,
Uganda
Seely, 2012
Male 2009–10 2011 450 652 34 4.5 (3.1, 6.7) 0.59
(Continued)
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up time included in this report. Data analysis was done with Stata (v12, College Park, TX,
USA).
Ethical approval of clinical research
Prior to enrollment, all volunteers underwent an informed consent procedure and written in-
formed consent was documented. Ethical approvals in each country were obtained from the
Kenya Medical Research Institute Ethical Review Committee, the Kenyatta National Hospital
Ethical Review Committee of the University of Nairobi, the Rwanda National Ethics Commit-
tee, the Uganda Virus Research Institute Science and Ethics Committee, the Uganda National
Council of Science and Technology, the University of Cape Town Health Science Research and
Ethics Committee, the University of Zambia Research Ethics Committee, the Bio-Medical Re-
search Ethics Committee at the University of KwaZulu Natal, and the Emory University Insti-
tutional Review Board.
Results
1. HIV prevalence and associated risk factors in Masaka, Nairobi and
Kilifi
From January to December 2004, 4,428 volunteers were enrolled at three CRCs in a cross-sec-
tional study of HIV prevalence. Prevalence varied from 8% to 16%; women and older volun-
teers had a significantly higher HIV prevalence at each CRC (Table 1). Marital status was
associated with HIV infection only at Kilifi, with divorced/widowed and polygamously married
volunteers two to three times more likely to be HIV infected than volunteers who had never
been married. In Masaka, residing in the community situated along the Kampala-Kigali trans-
African highway was associated with a 50% higher HIV prevalence compared to two villages
off the highway. In Kilifi, residents of urban areas were four times as likely to be HIV infected
as were rural volunteers. In Masaka, inconsistent condom use relative to never using a condom
was associated with HIV, and in Nairobi report of ever having used a condom was associated
with HIV infection. Report of genital ulcers was associated with a 1.5 to 2.5-fold increase in
HIV in Masaka and Kilifi. In Nairobi, marijuana use was associated with a two-fold increased
likelihood of HIV infection. In Masaka, report of a single, steady partner was inversely associat-
ed with HIV infection relative to report of no sexual partners in the past 3 months.
Table 2. (Continued)
CRC and study
population
Enrollment
years
Year of last
study visit
Total
enrolled
Total
PY
HIV cases
detected
HIV
incidence
95% CI p value** ref.***
Female 2009–10 2011 550 554 25 5.2 (3.7, 7.3)
* IAVI support initiated in 2004
** p value for the incident rate ratio calculator comparing HIV incidence by sex, where study populations are stratiﬁed by sex
*** For additional details on recruitment, demographics, follow up and earlier reports of HIV incidence. With the exception of Feldblum 2012, all the data
above and in Table 3 represents new analyses and additional follow up time.
▪ Cohort enrollment currently open
▪▪ Recruited women from 16 years old; the only cohort to recruit <18 year olds
1 HIV positive partner in the DC cohort is on ART, too few to analyze by volunteer sex (87 negative men, 65 women)PY: Person years, IQR: Interquartile
range, CI: Conﬁdence Interval, CRC: Clinical Research Center, DC: Discordant Couple (reported sex applies to enrolled HIV uninfected volunteers, HIV
infected volunteers were all ART-naive except where noted), NA: reference not available, data not previously published
doi:10.1371/journal.pone.0116100.t002
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2a. HIV incidence in discordant couples
From 2002 to 2011, 1,856 couples discordant for HIV status were enrolled in Kigali (Table 2).
HIV incidence was similar among women and men (p = 0.16). HIV incidence was nearly
2.5 times higher in the first three months of follow-up compared to subsequent visits for men
(p = 0.003, Table 3), but for women this only achieved borderline significance. HIV incidence
did not drop significantly with calendar year in Kigali (Table 3).
From 1995 (2004 in Ndola) to 2011, 3,800 HIV-discordant couples were enrolled at two
CRCs in Zambia (Table 2). HIV incidence was similar across the two CRCs (p = 0.71) and
was significantly higher in women compared to men in both Lusaka (p = 0.003) and Ndola
(p = 0.01). HIV incidence in the first three months of study follow-up was significantly higher
than in subsequent visits for women at both CRCs (Table 3), but the same was true only for
men in Lusaka. With the exception of Lusaka women, HIV incidence did not vary significantly
by year (Table 3), although a trend was also borderline significant among men in Ndola.
From 2006 through 2011, 1,574 couples were enrolled at both Ugandan CRCs, including
152 couples in Masaka who contributed follow-up while the HIV infected partner was on ART
(Table 2). HIV incidence did not vary by sex (Table 2) but was significantly lower in Entebbe
than in Masaka (p = 0.02). Masaka was the only CRC that enrolled discordant couples with the
positive partner on ART, and HIV incidence was significantly lower in couples on ART com-
pared to those not on ART (p = 0.009). In 2009, enrollment criteria changed in Masaka. There
was no evidence of a drop in HIV incidence by time on study (Entebbe and Masaka) or by cal-
endar year (Masaka) (Table 3).
2b. HIV incidence in men who have sex with men
In August 2005, the Kilifi, Kenya, CRC enrolled the first MSM into their HIV incidence cohort
study. Through December 2012, 726 MSM have been enrolled in Kilifi and enrollment is ongo-
ing; from January 2006-October 2009, 303 were enrolled in Nairobi; and from April 2009-
November 2010, 29 in Rustenburg, South Africa. HIV incidence has been very high in these co-
horts, from 5–10 cases/100 person-years (Table 2). Incidence dropped three-fold after the first
three months on-study in Kilifi (Table 3, p<0.001); no similar drop was observed in Nairobi.
No drop was observed in HIV incidence by calendar time (Kilifi).
2c. HIV incidence in Ugandan fishing communities
Between February and August 2009, 1,000 volunteers were enrolled from five fishing commu-
nities near Entebbe and Masaka, Uganda, into an 18-month prospective study. The overall
HIV incidence was 4.9 cases/100 PY and did not vary by sex (Table 2) or by recruitment area.
No evidence for a reduction in HIV incidence with time on study was observed (Table 3). Rela-
tively low HIV incidence was observed among adolescents (ages 13–17: 2.8 cases/100 PY),
however few enrolled (n = 26). Using updated screening criteria based on these results, a fur-
ther 529 volunteers were enrolled in the Masaka district from January 2012; follow-up is ongo-
ing and HIV incidence is high (6.7 cases/100 PY), particularly among women (Table 2).
2d. HIV incidence in other key populations
Other cohorts include female sex workers (FSW) in Kilifi [20], younger women in Cape Town
[20], and women enrolled from the community and local clinics in Rustenburg [25] (Table 2).
In 2010, the Rustenburg CRC shifted recruitment strategies into poorer, peripheral communi-
ties where HIV prevalence was higher. Eligibility criteria were also changed to include any
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Table 3. HIV incidence stratiﬁed by duration of time in study follow up, and (where data were
available) by study year.
CRC and study population Total
PY
HIV cases
detected
HIV
incidence
95% CI p value*
HIV discordant couples
Kigali, Rwanda: male negative
First 3 months of follow up 238 17 7.2 (4.2, 11.5) 0.003
>3 months of follow up 1615 47 2.9 (2.1, 3.9)
2002–2006 947 38 4.0 (2.8, 5.5) 0.20
2007–2011 896 26 2.9 (1.9, 4.3)
Kigali, Rwanda: female
negative
First 3 months of follow up 219 10 4.6 (2.2, 8.4) 0.08
>3 months of follow up 1494 35 2.3 (1.6, 3.3)
2002–2006 863 19 2.2 (1.3, 3.4) 0.27
2007–2011 842 26 3.1 (2.0, 4.5)
Lusaka, Zambia: male negative
First 3 months of follow up 404 39 9.7 (6.9, 13.2) 0.02
>3 months of follow up 2979 187 6.3 (5.4, 7.2)
2003–2006 1152 75 6.5 (5.1, 8.2) 0.67
2007–2011 1058 64 6.1 (4.7, 7.7)
Lusaka, Zambia: female
negative
First 3 months of follow up 341 51 15.0 (11.1,
19.7)
<0.001
>3 months of follow up 2520 201 8.0 (6.9, 9.2)
–2006 848 91 10.7 (8.6, 13.2) 0.001
2007–2011 741 44 5.9 (4.3, 8.0)
Ndola, Zambia: male negative
First 3 months of follow up 99 6 6.1 (2.2, 13.2) 0.96
>3 months of follow up 479 29 6.1 (4.1, 8.7)
2004–2007 290 23 7.9 (5.0, 11.9) 0.07
2008–2011 284 12 4.2 (2.2, 7.4)
Ndola, Zambia: female
negative
First 3 months of follow up 79 15 19.1 (10.7,
31.5)
0.02
>3 months of follow up 322 28 8.7 (5.8, 12.6)
2004–2007 168 23 13.7 (8.7, 20.5) 0.14
2008–2011 231 20 8.7 (5.3, 13.4)
Masaka, Uganda: male negative (excluding females on ART)
First 3 months of follow up 127 3 2.4 (0.8, 7.4) 0.39
>3 months of follow up 1017 41 4.0 (3.0, 5.5)
2006–2008 442 20 4.5 (2.9, 7.0) 0.36
2009–2011 701 24 3.4 (2.3, 5.1)
Masaka, Uganda: female negative (excluding males on ART)
First 3 months of follow up 70 4 5.8 (2.2, 15.3) 0.64
>3 months of follow up 445 20 4.5 (2.9, 7.0)
2006–2008 150 10 6.7 (3.6, 12.4) 0.19
2009–2011 365 14 3.8 (2.3, 6.5)
(Continued)
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woman reporting sexual activity or an STI. Over 300 women enrolled in Rustenburg with these
eligibility criteria had an HIV incidence of nearly 9 cases/100PY (Table 2).
2. Epidemiologic linkages in the early HIV infection cohort
From February 2006 through December 2011, 613 volunteers with incident HIV infection were
enrolled. The cohort comprised 255 (41.5%) women and 359 (58.5%) men, of whom 92
(25.6%) were MSM; all but three from Kenya. Most volunteers (460, 75.0%) were enrolled from
HIV-discordant couples cohorts, 219 (47.6%) were women.
For 407 volunteers, suspected transmitting partners were enrolled, 393 (96.6%) of whom
had sample to test HIV transmission linkages. The proportion of volunteers linked by HIV
Table 3. (Continued)
CRC and study population Total
PY
HIV cases
detected
HIV
incidence
95% CI p value*
Entebbe, Uganda: male
negative
First 3 months of follow up 61 2 3.3 (0.8, 13.2) 0.36
>3 months of follow up 284 4 1.4 (0.5, 3.7)
Entebbe, Uganda: female negative
First 3 months of follow up 72 2 2.8 (0.7, 11.1) 0.89
>3 months of follow up 344 9 2.6 (1.4, 5.0)
Men who have sex with men
Nairobi, Kenya
First 3 months of follow up 64 5 7.8 (3.2, 18.7) 0.42
>3 months of follow up 274 14 5.1 (3.0, 8.6)
Kiliﬁ, Kenya
First 3 months of follow up 94 15 16.0 (9.6, 26.5) <0.001
>3 months of follow up 829 43 5.2 (3.8, 7.0)
2005–2008 304 25 8.2 (5.6–12.2) 0.49
2009–2012 692 48 6.9 (5.2–9.2)
At-risk women
Cape Town, South Africa: Sexually active women
First 3 months of follow up 76 4 5.2 (2.0, 14.0) 0.18
>3 months of follow up 207 4 1.9 (0.7, 5.1)
Rustenburg, South Africa: Sexually active women
First 3 months of follow up 65 8 12.3 (6.2, 24.7) 0.28
>3 months of follow up 149 11 7.4 (4.1, 13.4)
Fishing Community members
Masaka, Uganda (2012–2013 cohort)
First 3 months of follow up 119 9 7.6 (3.9,14.6) 0.25
>3 months of follow up 383 18 4.7 (3.0,7.5)
Masaka & Entebbe, Uganda (2009–2010 cohort)
First 6 months of follow up** 417 23 5.5 (3.7, 8.3) 0.28
>6 months of follow up 803 33 4.1 (2.9, 5.8)
* Comparing HIV incidence in the ﬁrst three months to HIV incidence in subsequent months of follow up
and HIV incidence in the ﬁrst set of calendar years indicated to the subsequent set of years, where data
were available
** First return visit for this cohort was at six months post enrollment
doi:10.1371/journal.pone.0116100.t003
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sequence similarity to their suspected transmitting partner ranged from 67.1% in the Copper-
belt (Kitwe and Ndola) to 100% in Entebbe but these differences did not quite achieve signifi-
cance (Table 4, p = 0.08, Fisher’s exact test), and they did not vary by the sex of the incident
case (p = 0.27). In Kigali, a non-significant trend suggested women with incident HIV were
more commonly linked to their partners than were men (36/41 [87.8%] vs. 38/52 [73.1%],
respectively, p = 0.08).
Discussion
From 2004 to present, IAVI has coordinated HIV observational epidemiology studies at nine
CRCs in preparation for HIV prevention trials. Laboratory, clinical, and data management pro-
cedures were standardized to ensure comparability across CRCs. Research protocols typically
began with 1) cross-sectional HIV prevalence research, followed by 2) HIV incidence cohorts,
and then 3) early HIV infection cohorts. 4,428 volunteers were initially enrolled in Kenya and
Uganda, and HIV prevalence was observed to be higher than the national average, even in the
general population survey in Masaka. Nine CRCs enrolled over 10,000 HIV-negative volun-
teers in prospective studies of HIV incidence, which ranged from 2% to 10% annually. This
work included the first prospective studies of HIV incidence in African MSM [20, 26]. Over
600 volunteers with incident infection were enrolled from these cohorts into the early HIV in-
fection study. Among those with an identified HIV-positive regular sexual partner, about 28%
of HIV transmissions were not from that partner.
Prospective studies remain the gold standard for obtaining reliable HIV incidence data [6]
needed for informed decision making, from national level program planning to clinical trial de-
sign. However, prospective incidence studies are expensive, time consuming, and require real-
time review of data to maintain focus on a study cohort that reflects true risk of HIV infection.
While a goal of the 2004 prevalence studies was to guide selection of key populations, some
populations with elevated HIV prevalence had low HIV incidence. This included data from
rural villages in Masaka district [19] where a previous HIV prevention trial had been conducted
[27], heterosexual men in Kenya [20], FSW in Nairobi [20] and HIV discordant couples in
Table 4. Number of volunteers with HIV sequence data who enrolled with their suspected partner
and were epidemiologically linked.
Enrolled Linked
N N % p value
Total 393 282 71.8
RC and country
Kigali, Rwanda 93 74 79.6 0.08*
Lusaka, Zambia 145 100 70.0
Copperbelt, Zambia 76 51 67.1
Kiliﬁ, Kenya 4 3 75.0
Entebbe, Uganda 12 12 100.0
Masaka, Uganda 63 42 66.7
Sex of incident case
Male 220 153 69.5 0.27
Female 173 129 74.6
RC: Research Center
*Fisher’s exact test
doi:10.1371/journal.pone.0116100.t004
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Kilifi (no observed HIV incidence, unpublished data). In Masaka, the investigative team shifted
focus to HIV discordant couples and, later, to residents of fishing communities. In Kenya the
focus changed to MSM when men came forward asking to enroll as sex workers. Among MSM
along the coast, the Kilifi team recorded HIV incidence as high as 35 cases/100PY among those
who report sex exclusively with other men [26] highlighting both the success of careful epide-
miology and the extreme need for intervention. Collateral benefits from our work in MSM and
sex workers include the development of health care provider training modules to strengthen
service delivery to these marginalized groups [15], and the improvement of our outreach and
educational activities within the larger community. Following an attack on our Kilifi clinic that
took place in 2010 [28] an emphasis was placed on engaging a wide range of public officials
and public health stake holders, from religious leaders to government and police officials, and a
community liaison officer has been hired whose role is to manage this process of outreach and
education. Each CRC successfully identified key populations both suitable for HIV prevention
trials and in need of specialized program planning to reduce HIV transmission [15–17].
Among those cohorts where higher risk was observed, we recorded heterogeneity associated
with volunteer sex, time on study, and calendar year. Women are frequently cited as at signifi-
cant risk for HIV acquisition in Africa [29], and in five of the seven cohorts with men and
women the incidence point estimate reflected this (Table 2), although this achieved statistical
significance only in Zambia. Of the more than a dozen cohorts presented in Table 3, five (men
in discordant couples at Lusaka, Ndola, and Kigali; women in Ndola; and MSM in Kilifi) re-
corded a reduction in HIV incidence after the first study follow-up visit. While pre-
seroconversion HIV infection at enrollment may artificially inflate HIV incidence at the first
follow-up visit, we employed the p24 antigen assay at every study visit thereby excluding some
volunteers at enrollment prior to antibody seroconversion. Nine cohorts in table 3 had ade-
quate follow-up time to consider HIV incidence as a function of calendar year. Only female
members of DCs in Lusaka showed a statistically significant reduction in HIV incidence. Of
the 16 cohorts reported in Table 3, 5 demonstrate a significant drop in HIV incidence, 9 show
a non-significant drop in the incidence point estimate, 1 shows no change, and 1 shows a non-
significant increase in the point estimate. We feel the most likely reason for the drop in HIV in-
cidence was the regular counseling and testing and prevention messages, however, some co-
horts were simply not powered to detect this drop (e.g., MSM in Nairobi, women in Cape
Town and Rustenburg saw a non-significant drop of ~3 cases per 100 person years. This would
otherwise represent a very large drop, but in our case, it remains non-significant in a 200–300
person cohort). Additionally, the different stages of the epidemic in different countries and co-
horts may explain why we observe no significant changes in incidence, as perhaps some mature
epidemics may be less susceptible to intervention. Cohort recruitment may change subtly over
time as new clients seek HIV testing at the CRCs. Secular trends in the source populations such
as increased awareness of HIV prevention techniques may also be prevalent. Counseling and
prevention messages improve as health care providers get to know their stakeholders better.
Treatment and care changes as antiretroviral therapy guidelines change, affecting risk of HIV
acquisition in certain populations (e.g., HPTN 052 and the recommendation that ART be initi-
ated in HIV-discordant couples). National level program planning requires incidence trends
over time to best assess whether interventions are working or not. Clinical trial design (particu-
larly sample size) should always factor in anticipated decline in incidence during the time of
study as a result of national program interventions and that of the study itself. Taken as a
whole, these data suggest that in our cohorts HIV incidence tends to be lower in men than
women, declines with time on study, and may drop with calendar time. It is with caution that
one should generalize findings in research cohorts to the broader community; however this is
similar to overall trends in the African epidemic [2, 29].
HIV Epidemiology in African Trial Sites
PLOS ONE | DOI:10.1371/journal.pone.0116100 January 20, 2015 14 / 19
Volunteers with incident HIV infection from our discordant couple cohorts provide an in-
teresting lesson on risk that applies both to the clinical trialist and the public policy maker.
Some of the highest HIV incidence was observed in these cohorts, with incidence estimates up
to 10 cases /100PY. The HIV incidence among discordant couples who are not receiving quar-
terly behavioral counseling interventions is likely to be higher—possibly as high as 20–25% an-
nually [30, 31]. Following the results of HPTN 052, which demonstrated a 96% reduction of
HIV transmission within discordant couples when the volunteer with HIV infection received
ART early [32], considerable attention has been focused on “test and treat” (i.e., putting newly
diagnosed HIV-positive persons on ART as quickly as possible) as a means to reduce HIV
transmissions [33, 34], and discordant couples represent a priority [35]. While others point out
that real-world adherence, funding, and logistics all provide significant hurdles to this lofty
goal [36], our data highlight another challenge: up to 30% of infections in our discordant cou-
ple cohorts originated from a partner other than the HIV infected steady partner. Indeed, in
HPTN 052, 7 (17.9%) of the 39 transmission events were linked to someone other than the vol-
unteer’s enrolled HIV-positive partner [32]. Although “test and treat”may eventually be a
practical reality for much of the world’s population living with HIV, until that time discordant
couples remain an important key population for public health interventions and for study.
We enrolled thousands of volunteers at risk for HIV infection, hundreds of volunteers with
incident HIV infection, and identified key populations in need of public health interventions
who might be suitable to participate in the next generation of HIV prevention trials. This work
has spearheaded improvements to the health care delivery for marginalized groups such as sex
workers and MSM [15] and reinforced the importance of testing and counseling couples to-
gether [30, 37, 38]. Specimens from these studies have also been the basis for dozens of ongoing
collaborations ranging from estimating the seroprevalence of potential vaccine vectors [39] to
characterizing the transmitted virus [40]and the host immune system following infection [41,
42]. IAVI has also tested 13 HIV vaccine products in 25 early-phase clinical trials in Africa
[43–47], conducted a multi-site study to establish adult safety laboratory reference ranges
against which to characterize adverse events in these clinical trials [48], and enrolled over 1,800
asymptomatic volunteers with prevalent HIV infection in a search for broadly neutralizing an-
tibodies [49]. Collateral benefits extend beyond these CRCs as GCLP and assay-specific train-
ing are made available to laboratory technicians outside this partnership.
These large prospective observational epidemiology studies provide valuable data for pre-
vention trial design and conduct, prevention planning, and service delivery. Over the past nine
years, IAVI has identified and enrolled thousands of volunteers from key populations, observ-
ing a high HIV incidence despite regular HIV testing and counseling. The benefits to the public
health, scientific and local communities are tremendous.
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